IMMUNOCON
Controlling immunity with small molecules for a better therapy
The IMMUNOCON project aims to advance EMT-224, a first-in-class small molecule immune activator, towards clinical readiness to address the urgent need for effective therapies for late-stage solid cancers, such as colorectal cancer (CRC). CRC is the third most common cancer globally, with limited treatment options for advanced stages, resulting in poor prognosis and high mortality
rates. While immunotherapies, such as immune checkpoint inhibitors (ICIs) have revolutionized management of certain solid cancers, many CRC patients do not respond to treatment due to the immunologically 'cold' nature of these tumors.
EMT-224 represents a potential breakthrough in immunotherapy by converting 'cold' tumors into 'hot' ones, thereby enhancing the efficacy of ICIs. This innovation builds on results from the ERC Proof of Concept project IMMUNOSTIM, where EMT-224 was identified as a potent immune activator capable of breaking cancer immune evasion mechanisms. The IMMUNOCON project will
finalize the pre-clinical validation of EMT-224, focusing on its safety and efficacy in in vivo cancer models. This will involve comprehensive lead optimization, followed by preparing for CTA and GMP manufacturing, and a comprehensive commercial roadmap.
The project will also establish a robust business strategy for EMUNO Therapeutics GmbH (EMT), positioning it as a leading early drug discovery company in the immunotherapy field. The goal is to mature EMT to support the clinical development and eventual commercialization of EMT-224, which has strong 'pipeline-in-a-product' potential for a broad range of solid cancers. By the end of the project, EMT-224 will be poised for CTA-enabling studies, marking a significant step towards bringing a
novel, effective treatment to patients suffering from late-stage CRC and potentially other cancers.
UPDATE AFTER PROJECT YEAR 1
Work performed and main achievments
Work performed and main achievements
During the first year, IMMUNOCON progressed EMUNO Therapeutics’ immune activator EMT‑224 towards clinical readiness. Activities focused on generating robust pre‑clinical efficacy and safety data, optimizing the chemical series and laying the regulatory and manufacturing groundwork.
Results beyond the state of the art
IMMUNOCON pioneers a new direction in cancer immunotherapy by exploring small‑molecule activation of a unique pathway in innate immune cells. EMT is developing a new class of compounds that can stimulate highly potent but timely limited immune responses. During the first year of the project, EMT established translational assays and biomarker‑based in vivo models to guide the selection of promising candidates and confirm that the approach can mobilize anti‑tumor immunity.
Evidence from pre‑clinical studies suggests that this can convert immunologically “cold” tumours into “hot” tumors and enhance the effectiveness of immune checkpoint therapies. These technological achievements lay a foundation for novel therapeutics that patients with limited treatment options could benefit from and support Europe’s ambition to lead in next‑generation immuno‑oncology.
The long‑term impact of this work depends on successful implementation of a regulatory and manufacturing framework, collaboration with clinical partners, and commercialization to bring EMT's first‑in‑class immune activator to the clinic. Moreover, the project underscores the importance of local production networks and ethically responsible research, contributing to the strategic autonomy and sustainability objectives of the European Union.
Policy relevant evidence of our project
IMMUNOCON’s outcomes align with European policy priorities:
Support novel immunotherapies addressing unmet needs
By developing a treatment for colorectal cancers that do not respond to current immunotherapies, IMMUNOCON contributes to Europe’s Beating Cancer Plan and Horizon Europe’s focus on patient‑centered innovation.
Strengthen SME ecosystems
Early engagement with investors and partners shows that combining scientific grants with business support is vital for biotech success. Policies that couple research funding with business coaching, IP management and investor access should be expanded.
Promote strategic autonomy and local manufacturing
The project’s reliance on EU‑based CROs and partners strengthens Europe’s biopharmaceutical supply chain and reduces transport‑related emissions. Policies that incentivize local production and SME partnerships could enhance resilience.
Integrate environmental considerations
Selecting local partners and designing efficient chemical processes minimizes environmental impact. Health innovation policies should incorporate sustainability criteria
For further information on the IMMUNOCON project please consult the CORDIS database.
Disclaimer:
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.